Zhejiang Starry Pharmaceutical Co.,Ltd.
603520.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.82B
Close$
Share Statistics
| Market cap | $3.82 Billion |
|---|---|
| Enterprise Value | $6.45 Billion |
| Dividend Yield | $0.30 (3.44%) |
| Earnings per Share | $0.02 |
| Beta | 0.49 |
| Outstanding Shares | 438,409,881 |
Return
| Return on Equity | 0.85% |
|---|---|
| Return on Assets | 0.35% |
| Return on Invested Capital | 1.70% |
Valuation & Multiples
| P/E Ratio | 182.05 |
|---|---|
| PEG | 643.53 |
| Price to Sales | 1.68 |
| Price to Book Ratio | 1.68 |
| Enterprise Value to Revenue | 2.62 |
| Enterprise Value to EBIT | 97.34 |
| Enterprise Value to Net Income | 306 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 1.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$703.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$708.15 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zhejiang Starry Pharmaceutical Co.,Ltd.
1,905 employees
CEO: Weiyi Shen Founded in 1997 and headquartered in Xianju, China, Zhejiang Starry Pharmaceutical Co.,Ltd. specializes in the research, production, and global distribution of X-CT non-ionic contrast agents and fluoroquinolone pharmaceuticals, along wit...